Literature DB >> 8973567

Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes.

L Diomede1, S Sozzani, W Luini, M Algeri, L De Gioia, R Chiesa, P M Lievens, O Bugiani, G Forloni, F Tagliavini, M Salmona.   

Abstract

Prion-related encephalopathies are characterized by the intracerebral accumulation of an abnormal isoform of the cellular prion protein (PrPC) named scrapie prion protein (PrPSc). The pathological forms of this protein and its cellular precursor are not only expressed in the brain but also, at lower concentrations, in peripheral tissues. We recently showed that a synthetic peptide corresponding to residues 106-126 [PrP-(106-126)] of the human PrP is toxic to neurons and trophic to astrocytes in vitro. Our experiments were aimed at verifying whether PrP-(106-126) and other peptides corresponding to fragments of the amyloid protein purified from brains of patients with Gerstmann-Sträussler-Scheinker disease-namely PrP-(89-106), PrP-(106-114), PrP-(127-147)-were capable of stimulating circulating leucocytes. Native PrP expression in human lymphocytes, monocytes and neutrophils was first confirmed using PCR amplification of total RNA, after reverse transcription, and immunoblot analysis of cell extracts with anti-PrP antibodies. PrP-(106-126), but not the other peptides, increased membrane microviscosity, intracellular Ca2+ concentration and cell migration in circulating leucocytes, and O2-. production in monocytes and neutrophils. Membrane microviscosity was determined by the fluorescence polarization technique, using diphenylhexatriene as a probe, 300 s after the addition of PrP-(106-126) to the cell suspension in the concentration range 5-50 microM. The increase in intracellular Ca2+ elicited by PrP-(106-126) was dose-dependent in the range 5-500 microM. PrP-(106-126) stimulated O2-. production in monocytes and neutrophils in a dose- (10-300 microM) and time-(5-30 min) dependent manner in the presence of 10 microM dihydrocytochalasin B. Both the increase in Ca2+ concentration and the O2-. production were partially sensitive to pertussis toxin. PrP-(106-126) stimulated leucocyte migration in a dose-dependent (30-300 microM) manner and, at the highest concentration used, this migration was comparable with that elicited by 2.5 nM interleukin 8 or 10 nM fMet-Leu-Phe peptide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8973567      PMCID: PMC1217966          DOI: 10.1042/bj3200563

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  35 in total

1.  The signal transduction pathway involved in the migration induced by a monocyte chemotactic cytokine.

Authors:  S Sozzani; W Luini; M Molino; P Jílek; B Bottazzi; C Cerletti; K Matsushima; A Mantovani
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

2.  Cellular isoform of the scrapie agent protein participates in lymphocyte activation.

Authors:  N R Cashman; R Loertscher; J Nalbantoglu; I Shaw; R J Kascsak; D C Bolton; P E Bendheim
Journal:  Cell       Date:  1990-04-06       Impact factor: 41.582

3.  Scrapie prion proteins are synthesized in neurons.

Authors:  H A Kretzschmar; S B Prusiner; L E Stowring; S J DeArmond
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

Review 4.  Molecular biology of prion diseases.

Authors:  S B Prusiner
Journal:  Science       Date:  1991-06-14       Impact factor: 47.728

5.  Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein.

Authors:  C Selvaggini; L De Gioia; L Cantù; E Ghibaudi; L Diomede; F Passerini; G Forloni; O Bugiani; F Tagliavini; M Salmona
Journal:  Biochem Biophys Res Commun       Date:  1993-08-16       Impact factor: 3.575

6.  Changes in the localization of brain prion proteins during scrapie infection.

Authors:  S J DeArmond; W C Mobley; D L DeMott; R A Barry; J H Beckstead; S B Prusiner
Journal:  Neurology       Date:  1987-08       Impact factor: 9.910

7.  Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro.

Authors:  F Tagliavini; F Prelli; L Verga; G Giaccone; R Sarma; P Gorevic; B Ghetti; F Passerini; E Ghibaudi; G Forloni
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

8.  Presence of prion protein in peripheral tissues of Libyan Jews with Creutzfeldt-Jakob disease.

Authors:  Z Meiner; M Halimi; R D Polakiewicz; S B Prusiner; R Gabizon
Journal:  Neurology       Date:  1992-07       Impact factor: 9.910

9.  Neurotoxicity of a prion protein fragment.

Authors:  G Forloni; N Angeretti; R Chiesa; E Monzani; M Salmona; O Bugiani; F Tagliavini
Journal:  Nature       Date:  1993-04-08       Impact factor: 49.962

10.  Molecular cloning of a human prion protein cDNA.

Authors:  H A Kretzschmar; L E Stowring; D Westaway; W H Stubblebine; S B Prusiner; S J Dearmond
Journal:  DNA       Date:  1986-08
View more
  7 in total

1.  Sphingosine kinase-dependent migration of immature dendritic cells in response to neurotoxic prion protein fragment.

Authors:  Nicole C Kaneider; Arthur Kaser; Stefan Dunzendorfer; Herbert Tilg; Christian J Wiedermann
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 2.  Copper-dependent functions for the prion protein.

Authors:  David R Brown; Judyth Sassoon
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

3.  PrP(106-126) does not interact with membranes under physiological conditions.

Authors:  Sónia Troeira Henriques; Leonard Keith Pattenden; Marie-Isabel Aguilar; Miguel A R B Castanho
Journal:  Biophys J       Date:  2008-05-09       Impact factor: 4.033

4.  Human keratinocytes express cellular prion-related protein in vitro and during inflammatory skin diseases.

Authors:  J Pammer; W Weninger; E Tschachler
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

5.  Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126.

Authors:  M Salmona; P Malesani; L De Gioia; S Gorla; M Bruschi; A Molinari; F Della Vedova; B Pedrotti; M A Marrari; T Awan; O Bugiani; G Forloni; F Tagliavini
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

Review 6.  Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders.

Authors:  Adaze Bijou Enogieru; William Haylett; Donavon Charles Hiss; Soraya Bardien; Okobi Eko Ekpo
Journal:  Oxid Med Cell Longev       Date:  2018-06-27       Impact factor: 6.543

7.  Inhibition of cytosolic Phospholipase A2 prevents prion peptide-induced neuronal damage and co-localisation with Beta III Tubulin.

Authors:  Victoria Last; Alun Williams; Dirk Werling
Journal:  BMC Neurosci       Date:  2012-08-28       Impact factor: 3.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.